Skip to content

Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma (HCC): Real-world Experience from a US Community Oncology Network

IMbrave150 study, a phase III randomized control trial, showed statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) with atezolizumab-bevacizumab (atezo-bev) over sorafenib in patients with advanced hepatocellular carcinoma (HCC) who have never received any prior systemic therapies. This was a retrospective observational descriptive study of adult patients with advanced HCC who initiated 1L systemic treatment within The US Oncology Network between January 1, 2019 and July 31, 2021 (patients were followed through October 31, 2021).

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.

Not a healthcare professional? Browse:

Roche's patients website Roche.com

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically